AURX (Nuo Therapeutics) Asset Turnover: 0.69 (As of Mar. 2026)

What is Nuo Therapeutics Asset Turnover?

Nuo Therapeutics AURX 33 Asset Turnover is 0.69 as of Mar. 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.23 (Possible Value Trap). The stock has 4 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Nuo Therapeutics's Revenue for the three months ended in Mar. 2026 was $1.30 Mil. Nuo Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $1.90 Mil. Therefore, Nuo Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.69.

Asset Turnover is linked to ROE % through Du Pont Formula. Nuo Therapeutics's annualized ROE % for the quarter that ended in Mar. 2026 was 211.19%. It is also linked to ROA % through Du Pont Formula. Nuo Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -130.38%.

Nuo Therapeutics (OTCPK:AURX) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Nuo Therapeutics's annulized ROE % for the quarter that ended in Mar. 2026 is

	ROE %^**		(Q: Mar. 2026 )
=	Net Income	/	Total Stockholders Equity
=	-2.472	/	-1.1705
=	(Net Income / Revenue)	*	(Revenue / Total Assets)	*	(Total Assets / Total Stockholders Equity)
=	(-2.472 / 5.208)	*	(5.208 / 1.896)	*	(1.896/ -1.1705)
=	Net Margin %	*	Asset Turnover	*	Equity Multiplier
=	-47.47 %	*	2.7468	*	-1.6198
=	ROA %	*	Equity Multiplier
=	-130.38 %	*	-1.6198
=	211.19 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

^** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Nuo Therapeutics's annulized ROA % for the quarter that ended in Mar. 2026 is

	ROA %		(Q: Mar. 2026 )
=	Net Income	/	Total Assets
=	-2.472	/	1.896
=	(Net Income / Revenue)	*	(Revenue / Total Assets)
=	(-2.472 / 5.208)	*	(5.208 / 1.896)
=	Net Margin %	*	Asset Turnover
=	-47.47 %	*	2.7468
=	-130.38 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Nuo Therapeutics Asset Turnover Related Terms

Nuo Therapeutics Asset Turnover Historical Data

* Premium members only.

The historical data trend for Nuo Therapeutics's Asset Turnover can be seen below:

Nuo Therapeutics Asset Turnover Chart

Nuo Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Asset Turnover

Get a 7-Day Free Trial

0.00

0.05

0.25

0.89

2.18

Nuo Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Asset Turnover	Get a 7-Day Free Trial															0.41	0.56	0.63	0.58	0.69

AURX vs PDSB, LTRN, VERU: Asset Turnover Comparison

For the Biotechnology subindustry, Nuo Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuo Therapeutics Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Asset Turnover falls into.

Save Embed

33GF Score

Nuo Therapeutics Inc AURX

Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nuo Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Nuo Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (A: Dec. 2025 )	/	( (Total Assets (A: Dec. 2024 )	+	Total Assets (A: Dec. 2025 ))	/ count )
=	3.314	/	( (1.19	+	1.846)	/ 2 )
=	3.314	/	1.518
=	2.18

Nuo Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is calculated as

	Asset Turnover
=	Revenue	/	Average Total Assets
=	Revenue (Q: Mar. 2026 )	/	( (Total Assets (Q: Dec. 2025 )	+	Total Assets (Q: Mar. 2026 ))	/ count )
=	1.302	/	( (1.846	+	1.946)	/ 2 )
=	1.302	/	1.896
=	0.69

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →

What does a Asset Turnover of 0.69 mean?

Nuo Therapeutics (AURX) has a Asset Turnover of 0.69 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Nuo Therapeutics and its competitors.

Is Nuo Therapeutics' Asset Turnover too high?

Nuo Therapeutics' current Asset Turnover is 0.69. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Nuo Therapeutics' Asset Turnover compare to PDSB and LTRN?

Nuo Therapeutics' Asset Turnover of 0.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Asset Turnover for a Biotechnology company?

A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Asset Turnover mean?

A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Nuo Therapeutics and its competitors. Nuo Therapeutics's current Asset Turnover is 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nuo Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $1.01 — trading 76.1% below its estimated fair value. The current Asset Turnover is 0.69. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Asset Turnover calculated?

Asset Turnover is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Asset Turnover is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $1.01 is trading 76.1% below its estimated GF Value™ of $4.23. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

Asset Turnover: 0.69
GF Value™: $4.23 vs. price of $1.01 (76.1% below fair value)
GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nuo Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies PDSB LTRN VERU TIL KALA IBO MGX HYPD APLM CNTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054

Website https://www.nuot.com

Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.

33GF Score

Get the complete analysis for AURX

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01

Price

$4.23

GF Value

View AURX Analysis

See Asset Turnover data for all stocks →